Loading…
Avalyn Pharma Inc. is projected to rise to $29.73 by 2027, a +6% move from its current price of $28.06. Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $27.05 | $28.05 | $29.09 | -0.03% |
| Jul 14 | $26.64 | $28.04 | $29.52 | -0.07% |
| Jul 15 | $26.32 | $28.03 | $29.85 | -0.10% |
| Jul 16 | $26.06 | $28.02 | $30.14 | -0.13% |
| Jul 17 | $25.82 | $28.01 | $30.39 | -0.17% |
| Jul 18 | $25.62 | $28.00 | $30.61 | -0.20% |
| Jul 19 | $25.43 | $27.99 | $30.82 | -0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $25.43 | $27.99 | $30.82 | -0.23% |
| Week 2 | $24.37 | $27.93 | $32.00 | -0.47% |
| Week 3 | $23.58 | $27.86 | $32.92 | -0.70% |
| Week 4 | $22.93 | $27.80 | $33.70 | -0.94% |
| Week 5 | $22.36 | $27.73 | $34.39 | -1.17% |
| Week 6 | $21.86 | $27.67 | $35.02 | -1.40% |
| Week 7 | $21.40 | $27.60 | $35.61 | -1.63% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs.
Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc.
was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Avalyn Pharma Inc. (AVLN) is currently priced at $27.65. Its market capitalization is $1.23B and it is ranked 2399. The near-term technical picture is bearish, with a 30-day range of $21.25 to $35.98, and a defined support at $25.72 and resistance at $32.97. The trading range and volatility underline a cautious near-term posture for AVLN.
A major floor 22.8% below — a decisive break under it would weaken the trend.
The nearest floor, 8.3% below — buyers have tended to step in here.
The nearest ceiling, 17.5% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key AVLN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVLN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.40 | Sell | $28.72 | Sell |
| MA 10 | $29.65 | Sell | $29.18 | Sell |
| MA 20 | $29.83 | Sell | $29.34 | Sell |
| MA 50 | — | Neutral | — | Neutral |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.48 | Neutral |
| Stoch RSI (14) | 6.65 | Buy |
| CCI (20) | -89.22 | Neutral |
| Williams %R (14) | -92.29 | Info |
| MACD (12,26,9) | -0.31 | Sell |
| ROC (12) | -13.10 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 7.71 | Buy |
| TRIX (15) | 0.17 | Buy |
| Awesome (5,34) | -0.50 | Sell |
| Ultimate (7,14,28) | 28.30 | Buy |
| Momentum (10) | -0.92 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 28.07 | Sell |
| ADX (14) | 8.97 | Neutral |
| ATR (14) | 1.08 | Info |
The 30-day technical picture is bearish, with an RSI14 read of 40. This suggests cautious momentum in the near term.
Key support stands at $25.72 and resistance at $32.97, framing a defined near-term trading band. The 30-day price range runs from $21.25 to $35.98, illustrating notable volatility in the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.72 | $28.06 | $37.67 | 0% | Neutral | |
| $21.48 | $29.73 | $44.53 | +6% | Neutral | |
| $20.51 | $30.22 | $48.28 | +8% | Neutral | |
| $21.43 | $33.31 | $55.91 | +19% | Neutral | |
| $26.16 | $42.69 | $74.63 | +52% | Bullish | |
| $27.90 | $47.67 | $86.30 | +70% | Bullish | |
| $28.19 | $50.31 | $93.95 | +79% | Bullish | |
| $26.09 | $48.55 | $93.22 | +73% | Bullish | |
| $24.95 | $48.37 | $95.27 | +72% | Bullish | |
| $27.63 | $55.74 | $112.37 | +99% | Bullish | |
| $36.05 | $80.12 | $177.70 | +186% | Bullish | |
| $72.98 | $162.18 | $373.02 | +478% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $25.72 | $28.06 | $34.50 | +0.00% |
| August 2026 | $23.42 | $28.39 | $35.88 | +1.19% |
| September 2026 | $22.12 | $27.21 | $35.13 | -4.16% |
| October 2026 | $21.16 | $26.36 | $34.64 | -3.12% |
| November 2026 | $21.69 | $27.30 | $36.40 | +3.57% |
| December 2026 | $21.92 | $27.88 | $37.67 | +2.11% |
Click any year to see its month-by-month AVLN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Avalyn Pharma Inc.'s 2026 outlook centres on $28.06, within a $25.72 to $37.67 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, AVLN could reach as high as $44.53, with a base case around $29.73 and support toward $21.48 — roughly +6% from $28.06. A consolidation phase looks the most probable path here.
Expect AVLN to range from $20.51 to $48.28 through 2028. The $30.22 average target implies a +8% move from current prices. That is up +2% on the projected 2027 average. Price action looks broadly range-bound.
The AVLN price prediction for 2029 points to an average of $33.31 (low $21.43, high $55.91) — a potential gain of +19% on today's $28.06. A consolidation phase looks the most probable path here.
In 2030, AVLN is projected to trade between $26.16 and $74.63, averaging $42.69 — a potential gain of +52% from today's $28.06. That is up +28% on the projected 2029 average. Momentum favours further upside here.
Avalyn Pharma Inc.'s 2031 outlook centres on $47.67, within a $27.90 to $86.30 range. That is up +12% on the projected 2030 average. That marks a +70% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, AVLN could reach as high as $93.95, with a base case around $50.31 and support toward $28.19 — roughly +79% from $28.06. Momentum favours further upside here.
Expect AVLN to range from $26.09 to $93.22 through 2033. The $48.55 average target implies a +73% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The AVLN price prediction for 2034 points to an average of $48.37 (low $24.95, high $95.27) — a potential gain of +72% on today's $28.06. Momentum favours further upside here.
In 2035, AVLN is projected to trade between $27.63 and $112.37, averaging $55.74 — a potential gain of +99% from today's $28.06. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Avalyn Pharma Inc.'s 2040 outlook centres on $80.12, within a $36.05 to $177.70 range. That is up +44% on the projected 2035 average. That marks a +186% change versus current levels. Momentum favours further upside here.
By 2050, AVLN could reach as high as $373.02, with a base case around $162.18 and support toward $72.98 — roughly +478% from $28.06. Buyers look set to stay in control over this stretch.
Investing $1,000 in AVLN today (≈ 35.637919 AVLN) could be worth
$5,779.78
+$4,779.78 (+478%) by 2050 · US Dollar
Based on the average projected AVLN price of $162.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVLNwould be worth at today's price.
$1,000 invested in AVLN on Apr 30, 2026 (≈ 33.9098 AVLN) would be worth
$951.51
-$48.49 (-4.8%) today · 0.95× · US Dollar
Based on a AVLN entry price of $29.49 vs. today's $28.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.73 | $943.83 | -5.6% |
| 1 month ago | $28.53 | $983.53 | -1.6% |
| All time ago | $29.49 | $951.51 | -4.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVLN forecast.
Our base-case forecast reaches $56.00 around 2040.
Implied market cap at $56.00: $2.48B
The multi-year forecast shows a neutral to bullish transition over time. The years 2026 through 2029 are described as NEUTRAL, with average prices ranging from $27.65 to $30.66 and minimal ROI. The forecast becomes BULLISH from 2030 onward, with 2030 showing an average of $40.03 (min $23.50, max $72.32) and ROI of 44.8%.
2035 posts a higher average of $50.07 with a max of $105.18 and ROI of 81.1. 2040 projects a strong rise to an average of $71.94 (min $32.37, max $165.46) and ROI of 160.2. The long-term horizon culminates in 2050 with an average of $142.11 (min $63.95, max $326.84) and ROI of 413.9.
These are estimates, not guarantees, and actual outcomes depend on market and company-specific developments.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $40.03, with a min of $23.50 and a max of $72.32; ROI 44.8; sentiment BULLISH.
Forecasts show mixed near-term sentiment (NEUTRAL in 2026–2029) with gradual upside in later years; the 2030–2050 outlook includes higher average prices and ROIs (e.g., 2030 ROI 44.8%, 2040 ROI 160.2%, 2050 ROI 413.9%). These are estimates, not guarantees.
Yes. The forecast max values include $105.18 in 2035, $165.46 in 2040, and $326.84 in 2050.
Current price is $27.65 and market capitalization is $1.23B.
2026 avg $27.65 with min $25.72 and max $37.24; 2027 avg $28.52 with min $20.17 and max $43.71; 2028 avg $28.71 with min $18.93 and max $47.13; 2029 avg $30.66 with min $19.03 and max $53.05.
Avalyn Pharma Inc. Community Discussion
0Share your Avalyn Pharma Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.